Welcome to our dedicated page for Versamet Royalties news (Ticker: VMET), a resource for investors and traders seeking the latest updates and insights on Versamet Royalties stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Versamet Royalties's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Versamet Royalties's position in the market.
Versamet Royalties (NASDAQ: VMET) appointed Juan Presa to its Board of Directors effective March 13, 2026.
Mr. Presa joins as Tether Investments representative under an investor rights agreement and brings legal and capital markets experience, serving as General Counsel of Union Group since September 2020 and Corporate Execution Manager at Tether since November 2025.
Versamet (NASDAQ: VMET) reported record Q4 2025 and full‑year 2025 results driven by acquisitions, higher commodity prices and portfolio performance. Q4 revenue was $18.4M and FY revenue was $34.8M. Versamet raised equity, uplisted to TSX, commenced NASDAQ trading, and guided 20,000–23,000 GEOs for 2026.
The company repaid $80M of its term loan, expanded its revolving credit facility to $225M, and completed a C$142M financing to fund growth and portfolio opportunities.